{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:17:11Z","timestamp":1789510631549,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.urolonc.2024.06.012","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T16:06:13Z","timestamp":1721491573000},"page":"374.e11-374.e20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Socioeconomic and Demographic Disparities in Immunotherapy Utilization for Advanced Kidney and Bladder Cancer"],"prefix":"10.1016","volume":"42","author":[{"given":"Levi","family":"Holland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Bhanvadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathanaelle","family":"Ibeziako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7957-2715","authenticated-orcid":false,"given":"Deitrich","family":"Gerlt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iftach","family":"Chaplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Bagrodia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris","family":"Gaston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitaly","family":"Margulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3282-7670","authenticated-orcid":false,"given":"Solomon","family":"Woldu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2024.06.012_bib0001","unstructured":"SEER*Explorer. SEER Cancer Statistics. National Cancer Institute. Published April 19, 2023. Accessed October 30, 2023. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/."},{"issue":"5","key":"10.1016\/j.urolonc.2024.06.012_bib0002","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.11329","article-title":"Real-world survival outcomes associated with first-line immunotherapy, targeted therapy, and combination therapy for metastatic clear cell renal cell carcinoma","volume":"4","author":"Chakiryan","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.012_bib0003","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"20","key":"10.1016\/j.urolonc.2024.06.012_bib0004","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.3390\/cancers13205065","article-title":"Immunotherapies in genitourinary oncology: Where are we now? Where are we going?","volume":"13","author":"Jang","year":"2021","journal-title":"Cancers"},{"issue":"10064","key":"10.1016\/j.urolonc.2024.06.012_bib0005","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet Lond Engl"},{"issue":"10031","key":"10.1016\/j.urolonc.2024.06.012_bib0006","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet North Am Ed"},{"issue":"19","key":"10.1016\/j.urolonc.2024.06.012_bib0007","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.urolonc.2024.06.012_bib0008","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.urolonc.2024.06.012_bib0009","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.urolonc.2024.06.012_bib0010","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.urolonc.2024.06.012_bib0011","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/jnci\/94.5.334","article-title":"Racial and ethnic disparities in the receipt of cancer treatment","volume":"94","author":"Shavers","year":"2002","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.urolonc.2024.06.012_bib0012","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3322\/canjclin.54.2.78","article-title":"Cancer disparities by race\/ethnicity and socioeconomic status","volume":"54","author":"Ward","year":"2004","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.urolonc.2024.06.012_bib0013","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.19535","article-title":"Association between food and drug administration approval and disparities in immunotherapy use among patients with cancer in the US","volume":"5","author":"Ermer","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.urolonc.2024.06.012_bib0014","first-page":"228","article-title":"Racial and socioeconomic disparities in the delivery of immunotherapy for metastatic melanoma in the United States","volume":"42","author":"Haque","year":"2019","journal-title":"J Immunother Hagerstown Md 1997"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.012_bib0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.21037\/hbsn.2019.07.01","article-title":"Immunotherapy utilization for hepatobiliary cancer in the United States: Disparities among patients with different socioeconomic status","volume":"9","author":"Sahara","year":"2020","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"2","key":"10.1016\/j.urolonc.2024.06.012_bib0016","first-page":"55","article-title":"Racial and insurance-related disparities in delivery of immunotherapy-type compounds in the United States","volume":"42","author":"Verma","year":"2019","journal-title":"J Immunother Hagerstown Md 1997"},{"issue":"5","key":"10.1016\/j.urolonc.2024.06.012_bib0017","first-page":"2897","article-title":"Disparities of immunotherapy utilization in patients with stage III cutaneous melanoma: A national perspective","volume":"38","author":"Al-Qurayshi","year":"2018","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.012_bib0018","doi-asserted-by":"crossref","first-page":"8190","DOI":"10.1038\/s41598-023-35216-2","article-title":"Socioeconomic disparities in immunotherapy use among advanced-stage non-small cell lung cancer patients: Analysis of the national cancer database","volume":"13","author":"Gupta","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2024.06.012_bib0019","unstructured":"National Cancer Database Participant User Files. ACS. Accessed October 18, 2023. https:\/\/www.facs.org\/quality-programs\/cancer-programs\/national-cancer-database\/puf\/"},{"issue":"12","key":"10.1016\/j.urolonc.2024.06.012_bib0020","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1001\/jamaoncol.2016.6905","article-title":"Using the national cancer database for outcomes research: A review","volume":"3","author":"Boffa","year":"2017","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2024.06.012_bib0021","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1634\/theoncologist.2016-0476","article-title":"FDA approval summary: Nivolumab in advanced renal cell carcinoma after anti-angiogenic therapy and exploratory predictive biomarker analysis","volume":"22","author":"Xu","year":"2017","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.urolonc.2024.06.012_bib0022","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1634\/theoncologist.2018-0084","article-title":"FDA approval summary: Atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy","volume":"24","author":"Suzman","year":"2019","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.012_bib0023","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12916-020-01753-0","article-title":"Are there socio-economic inequalities in utilization of predictive biomarker tests and biological and precision therapies for cancer? A systematic review and meta-analysis","volume":"18","author":"Norris","year":"2020","journal-title":"BMC Med"},{"issue":"10","key":"10.1016\/j.urolonc.2024.06.012_bib0024","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/jnci\/djad132","article-title":"Unequal racial distribution of immunotherapy for late-stage non-small cell lung cancer","volume":"115","author":"Chang","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.urolonc.2024.06.012_bib0025","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/08858190902854772","article-title":"Cancer information-seeking experiences: The implications of Hispanic ethnicity and Spanish language","volume":"24","author":"Vanderpool","year":"2009","journal-title":"J Cancer Educ"},{"issue":"3","key":"10.1016\/j.urolonc.2024.06.012_bib0026","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/cncr.22436","article-title":"Provider roles in the recruitment of underrepresented populations to cancer clinical trials","volume":"109","author":"Howerton","year":"2007","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.urolonc.2024.06.012_bib0027","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.1870","article-title":"Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018","volume":"5","author":"Loree","year":"2019","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2024.06.012_bib0028","article-title":"Speed of adoption of immune checkpoint inhibitors of programmed cell death 1 protein and comparison of patient ages in clinical practice vs pivotal clinical trials","volume":"4","author":"O'Connor","year":"2018","journal-title":"JAMA Oncol"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2024.06.012_bib0029","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e18610","article-title":"Rapid adoption of immunotherapy in community health systems, associated with changing treatment guidelines","volume":"40","author":"Winzeler-Cotton","year":"2022","journal-title":"J Clin Oncol"},{"issue":"40","key":"10.1016\/j.urolonc.2024.06.012_bib0030","doi-asserted-by":"crossref","first-page":"e12715","DOI":"10.1097\/MD.0000000000012715","article-title":"Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016: A cross-sectional study","volume":"97","author":"Roginiel","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.urolonc.2024.06.012_bib0031","doi-asserted-by":"crossref","first-page":"S1340","DOI":"10.1016\/j.annonc.2023.10.106","article-title":"LBA6 EV-302\/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC)","volume":"34","author":"Powles","year":"2023","journal-title":"Ann Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924005106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924005106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T06:49:08Z","timestamp":1725346148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924005106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1078143924005106"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.06.012","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Socioeconomic and Demographic Disparities in Immunotherapy Utilization for Advanced Kidney and Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}